.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
McKesson
Cantor Fitzgerald
Argus Health
Teva
AstraZeneca
US Army
Novartis
Chubb
Queensland Health

Generated: September 24, 2017

DrugPatentWatch Database Preview

Tesamorelin acetate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for tesamorelin acetate and what is the scope of tesamorelin acetate patent protection?

Tesamorelin acetate
is the generic ingredient in one branded drug marketed by Theratechnologies and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tesamorelin acetate has forty-two patent family members in sixteen countries.

Two suppliers are listed for this compound.

Summary for Generic Name: tesamorelin acetate

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Clinical Trials: see list935
Drug Prices:see low prices
DailyMed Link:tesamorelin acetate at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-001Nov 10, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-002Nov 29, 2011DISCNNoNo► Subscribe► Subscribe ► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-001Nov 10, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-002Nov 29, 2011DISCNNoNo► Subscribe► Subscribe ► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-001Nov 10, 2010RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: tesamorelin acetate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-001Nov 10, 2010► Subscribe► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-002Nov 29, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: tesamorelin acetate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,939,386 Chimeric fatty body-pro-GRF (1-29) analogs with increased biological potency► Subscribe
8,435,945GH secretagogues and uses thereof► Subscribe
8,314,066GH secretagogues and uses thereof► Subscribe
6,458,764 GRF analogs with increased biological potency► Subscribe
6,020,311 GRF analogs with increased biological potency► Subscribe
6,696,063 Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy► Subscribe
8,481,489GH secretagogues and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: tesamorelin acetate

Country Document Number Estimated Expiration
Canada2342070► Subscribe
World Intellectual Property Organization (WIPO)2006042408► Subscribe
World Intellectual Property Organization (WIPO)2004105789► Subscribe
Australia2005297366► Subscribe
Norway20072136► Subscribe
South Korea101228229► Subscribe
Austria204881► Subscribe
Australia2010200224► Subscribe
European Patent Office0828758► Subscribe
Australia2003229222► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Citi
Federal Trade Commission
US Army
Mallinckrodt
Moodys
Express Scripts
Accenture
Farmers Insurance
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot